GPCRs are vital drug targets because they control so many of the body’s fundamental physiological processes, including heart rate and blood pressure, glucose balance, immune cell activation, neurotransmission and behavior. When these processes go awry—whether in hypertension, asthma, depression, diabetes, or chronic inflammation—GPCR-targeting drugs can restore balance by activating the receptor when natural signaling is insufficient or blocking it when signaling is excessive. Their position on the cell surface makes GPCRs readily accessible to therapeutic compounds, and their ability to fine-tune cellular responses allows drugs that target them to achieve beneficial effects without systemic side effects. As a result, medications that act on GPCRs—such as beta-blockers, antihistamines and GLP-1 agonists—can effectively correct physiological dysfunction, offering powerful and precisely directed treatments for a broad range of human diseases and conditions.

Spectragenetics’ FAP technology expands the scope and accelerates the pace of GPCR drug discovery like nothing else, opening the door to therapies undreamed of today.